Surrozen (SRZN)
NASDAQ:SRZN
Want to see SRZN full AI Analyst Report?
Top Page
Surrozen
(NASDAQ:SRZN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$22.50
▼(-28.71% Downside)
Action:Reiterated
Date:05/15/26
The score is primarily held down by very weak financial performance (large ongoing losses, heavy cash burn, and negative equity). Technicals are relatively neutral with mild longer-term support, and valuation metrics provide limited support due to a negative P/E and no dividend yield data.
Positive Factors
Platform focus on Wnt signaling
Surrozen's concentrated scientific focus on modulating Wnt signaling is a durable strategic asset: the platform targets tissue repair across multiple organs (liver, intestine, eye), enabling potential multi-indication development, licensing, and long-term value creation if clinical validation proceeds.
Negative Factors
Persistent heavy cash burn
Sustained negative operating and free cash flow in the mid tens of millions annually creates an ongoing financing requirement. Over the next several months this structural cash burn forces reliance on external capital, risks dilution, and may constrain program advancement if funding terms worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform focus on Wnt signaling
Surrozen's concentrated scientific focus on modulating Wnt signaling is a durable strategic asset: the platform targets tissue repair across multiple organs (liver, intestine, eye), enabling potential multi-indication development, licensing, and long-term value creation if clinical validation proceeds.
Read all positive factors
Surrozen (SRZN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$269.94M
Dividend YieldN/A
Average Volume (3M)25.24K
Price to Earnings (P/E)―
Beta (1Y)-0.23
Revenue Growth-35.61%
EPS Growth-68.92%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-41.33
Shares Outstanding11,610,371
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit10.72
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$42.50Price Target Upside34.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$6.40M
Surrozen Business Overview & Revenue Model
Company Description
Surrozen, Inc. is a biotechnology firm dedicated to discovering and advancing pharmaceutical agents that precisely modify the Wnt pathway to facilitate tissue healing and regeneration. The company engineers specialized antibodies intended for use ...
How the Company Makes Money
Surrozen does not primarily generate revenue from product sales because it is a clinical-stage biotechnology company and, to the extent publicly available information indicates, it has no approved commercial products. Instead, when it earns revenu...
Surrozen Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.49M | 3.48M | 10.65M | 0.00 | 12.50M | 0.00 |
| Gross Profit | 7.43M | 2.94M | 10.65M | -27.23M | 9.23M | -3.30M |
| EBITDA | -342.25M | -241.49M | -62.12M | -41.13M | -34.05M | -51.35M |
| Net Income | -342.56M | -242.03M | -63.56M | -43.04M | -36.00M | -52.51M |
Balance Sheet | ||||||
| Total Assets | 120.71M | 98.73M | 48.47M | 46.08M | 89.44M | 137.17M |
| Cash, Cash Equivalents and Short-Term Investments | 106.91M | 89.25M | 34.56M | 36.04M | 75.84M | 101.85M |
| Total Debt | 6.78M | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Total Liabilities | 398.86M | 286.49M | 69.85M | 8.14M | 13.43M | 27.47M |
| Stockholders Equity | -278.15M | -187.76M | -21.38M | 37.94M | 76.00M | 109.70M |
Cash Flow | ||||||
| Free Cash Flow | -33.68M | -30.37M | -17.65M | -40.76M | -44.87M | -50.08M |
| Operating Cash Flow | -33.46M | -30.24M | -17.63M | -40.36M | -44.15M | -48.81M |
| Investing Cash Flow | -221.00K | -128.00K | -26.00K | 51.72M | 38.31M | -77.71M |
| Financing Cash Flow | 38.95M | 85.05M | 16.18M | 276.00K | -2.56M | 124.63M |
Surrozen Technical Analysis
Negative
31.56
Price Trends
27.87
Negative
26.77
Negative
21.32
Positive
Market Momentum
-1.36
Negative
42.96
Neutral
55.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Negative. The current price of 31.56 is above the 20-day moving average (MA) of 24.03, above the 50-day MA of 27.87, and above the 200-day MA of 21.32, indicating a neutral trend. The MACD of -1.36 indicates Negative momentum. The RSI at 42.96 is Neutral, neither overbought nor oversold. The STOCH value of 55.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRZN.
Surrozen Risk Analysis
Surrozen disclosed 85 risk factors in its most recent earnings report. Surrozen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Surrozen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $423.67M | -6.93 | -22.51% | ― | 1199.64% | 30.81% | |
47 Neutral | $144.11M | -1.93 | -155.40% | ― | -100.00% | 61.98% | |
46 Neutral | $336.04M | -33.07 | 6068.79% | ― | -12.22% | 30.28% | |
45 Neutral | $269.94M | -0.74 | 309.79% | ― | -35.61% | -68.92% | |
45 Neutral | $447.34M | -11.14 | -60.73% | ― | -78.29% | 54.16% | |
44 Neutral | $85.31M | -1.90 | -196.72% | ― | ― | 74.83% |
* Healthcare Sector Average
SRZN
Surrozen
23.25
14.23
157.76%
IRD
Opus Genetics
4.07
3.16
349.23%
OVID
Ovid Therapeutics
2.27
1.98
682.76%
STTK
Shattuck Labs
4.95
3.94
390.10%
SPRB
Spruce Biosciences
52.36
47.11
897.33%
BMEA
Biomea Fusion
1.18
-0.51
-30.18%
Surrozen Corporate Events
Executive/Board ChangesShareholder Meetings
Surrozen Shareholders Support Board, Auditor and Pay Policies
Positive
May 14, 2026
On May 13, 2026, Surrozen, Inc. held its 2026 Annual Meeting of Stockholders, with 7,744,669 of 11,486,707 entitled common shares represented in person or by proxy, and no solicitation in opposition to management. Stockholders elected Mace Rothenb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.